Sanofi Receives U.S. FDA Approval for Insulin Injection Admelog
12 December 2017 - 5:46PM
Dow Jones News
By Max Bernhard
Sanofi SA (SAN.FR) received approval for its follow-on mealtime
insulin injection Admelog by the U.S. Food and Drug Administration,
the company said late Monday.
Admelog will be available in the U.S. in vial form and as a
prefilled disposable insulin pen, Sanofi said.
The treatment is a follow-on insulin lispro--a fast-acting
insulin--for diabetics who need to manage blood sugar levels at
meal times, the company said.
Admelog received authorization from the European Commission in
July 2017 to be marketed as a biosimilar under the name Insulin
lispro Sanofi.
Write to Max Bernhard at Max.Bernhard@dowjones.com;
@mxbernhard
(END) Dow Jones Newswires
December 12, 2017 01:31 ET (06:31 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024